KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Novavax (NVAX) EBT (2016 - 2025)

Novavax has reported EBT over the past 16 years, most recently at $17.9 million for Q4 2025.

  • Quarterly results put EBT at $17.9 million for Q4 2025, up 124.33% from a year ago — trailing twelve months through Dec 2025 was $442.2 million (up 350.36% YoY), and the annual figure for FY2025 was $442.2 million, up 350.36%.
  • EBT for Q4 2025 was $17.9 million at Novavax, up from -$203.0 million in the prior quarter.
  • Over the last five years, EBT for NVAX hit a ceiling of $519.8 million in Q1 2025 and a floor of -$829.7 million in Q4 2021.
  • Median EBT over the past 5 years was -$155.7 million (2022), compared with a mean of -$132.3 million.
  • Biggest five-year swings in EBT: tumbled 1890.58% in 2021 and later surged 457.8% in 2025.
  • Novavax's EBT stood at -$829.7 million in 2021, then surged by 77.76% to -$184.5 million in 2022, then rose by 4.23% to -$176.7 million in 2023, then skyrocketed by 58.36% to -$73.6 million in 2024, then skyrocketed by 124.33% to $17.9 million in 2025.
  • The last three reported values for EBT were $17.9 million (Q4 2025), -$203.0 million (Q3 2025), and $107.5 million (Q2 2025) per Business Quant data.